Dihydrobenzimidazolones for medical treatment
The present invention provides selected dihydrobenzimidazolones which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and alter the substrate specificity of the CRBN E3 ubiquitin ligase complex, resulting in breakdown of intrinsic downstream proteins. The disclosed compounds are useful for the treatment of cancer.
1. A compound selected from
or a pharmaceutically acceptable salt thereof.
2. The compound of claim 1 of the formula
or a pharmaceutically acceptable salt thereof.
3. The compound of claim 1 of the formula
or a pharmaceutically acceptable salt thereof.
4. The compound of claim 1 of the formula
or a pharmaceutically acceptable salt thereof.
5. The compound of claim 1 of the formula
or a pharmaceutically acceptable salt thereof.
6. The compound of claim 1 of the formula
or a pharmaceutically acceptable salt thereof.
7. The compound of claim 1 of the formula
or a pharmaceutically acceptable salt thereof.
8. The compound of claim 1 of the formula
or a pharmaceutically acceptable salt thereof.
9. A compound selected from
or a pharmaceutically acceptable salt thereof.
10. The compound of claim 9 of the formula
or a pharmaceutically acceptable salt thereof.
11. The compound of claim 9 of the formula
or a pharmaceutically acceptable salt thereof.
12. The compound of claim 9 of the formula
or a pharmaceutically acceptable salt thereof.
13. The compound of claim 9 of the formula
or a pharmaceutically acceptable salt thereof.
14. A compound selected from
or a pharmaceutically acceptable salt thereof.
15. The compound of claim 14 of the formula
or a pharmaceutically acceptable salt thereof.
16. The compound of claim 14 of the formula
or a pharmaceutically acceptable salt thereof.
17. The compound of claim 14 of the formula
or a pharmaceutically acceptable salt thereof.
18. The compound of claim 14 of the formula
or a pharmaceutically acceptable salt thereof.
19. The compound of claim 14 of the formula
or a pharmaceutically acceptable salt thereof.
20. A pharmaceutical composition comprising a compound or pharmaceutically acceptable salt thereof of claim 1 optionally in a pharmaceutically acceptable carrier.
21. A pharmaceutical composition comprising a compound or pharmaceutically acceptable salt thereof of claim 9 optionally in a pharmaceutically acceptable carrier.
22. A pharmaceutical composition comprising a compound or pharmaceutically acceptable salt thereof of claim 14 optionally in a pharmaceutically acceptable carrier.